Icagen got some good news from an independent data monitoring committee, which has endorsed the advancement of a Phase III trial of its ICA-17043 compound in conjunction with hydroxyurea therapy for sickle cell disease. The same committee recommended last month that the trial of ICA-17043 alone should not continue, sending its shares into a free fall.
- read the Local Tech Wire report on Icagen